A recent report demonstrated that, in mice, the irAEs associated with anti-CTLA-4 antibody treatment were mediated by the lysosomal degradation of CTLA-4 and that the avoidance of degradation led to more effective tumor rejection with fewer irAEs [16]. The gene discussed is CTLA4; the disease is neoplasm.